Universities play a critical role in society

Public funds → Research Universities → Technology transfer offices → Private sector → Public good

Scientific papers
Trained workforce
University R&D is essential, but not sufficient

R&D Spending (Billion)

New York
San Francisco
Baltimore
Boston

The Center for an Urban Future, 2009
University R&D is essential, but not sufficient.
UC produces fewer startups

**Number of Startups 2004-2008**

- UC
- Stanford
- MIT
- CalTech

AUTM Data
Universities play a critical role in society

- Public funds
- Research Universities
- University/Private Sector Interface
- Private sector
- Public good

- Scientific papers
- Trained workforce
California Institutes for Science and Innovation

CITRIS (UCB, UCD, UCM, UCSC)
Center for Information Technology Research in the Interest of Society

QB3 (UCB, UCSC, UCSF)
California Institute for Quantitative Biosciences

CNSI (UCLA, UCSB)
California Nanosystems Institute

CAL-(IT)^2 (UCSD, UCI)
Institute for Telecommunications and Information Technology
QB3 INNOVATION TOOLKIT
QB3’s Innovation Toolkit: catalyzing company formation

QB3 uses its Innovation Toolkit to FIND opportunities, NURTURE their to commercial potential and help START to help launch new companies.
QB3’s knowledge brokers identify useful discoveries

Regis Kelly, PhD
QB3 Director

Marc A. Shuman, MD
QB3 Clinical Director
Professor, UCSF, Medicine, Urology, and Cancer Research Institute

Douglas Crawford, PhD
QB3 Director of Industry Alliances & Associate Executive Director

Tracy Saxton, PhD,
QB3 Industry Alliances Manager
QB3 provides essential “garage” space & advice
QB3 Garage@UCSF

Current members

- Allopartis
- Lypro Biosciences, Inc.
- OmniOx
- Photoswitch Biosciences
- Improta
- 100X Imaging

Alums

- True Materials
- Satoris
- Mynosys
- Bay Therapeutics
- Nidaan
  “Accurate Diagnosis”
A case study: with QB3’s support, Fluxion Biosciences completed $6.8M Series A funding

After support & guidance from QB3:

Fluxion won $101,000 Phase I SBIR grant
Moved into QB3 Garage
2 rounds of angel funding at about 12 months
$1.2 M Phase II SBIR grant about 14 months
$6.8 M Series A led by Kodiak Ventures, November 2007
QB3 Mission Bay Incubator Network

- Aliva Biopharmaceuticals
- Carmot Therapeutics
- CV Ingenuity
- Delpor
- Gemmus Pharma
- Green Pacific Biologicals
- Locus Development
- Metafold Therapeutics
- Medicus
- MLC Dx
- Osprey Pharmaceuticals
- Pharmajet
- Photoswitch Biosciences
- Siluria Technologies
- Solidus Biosciences
- Tunitas Therapeutics
QB3 venture fund to catalyze innovation

QB3 INNOVATION TOOLKIT

DISCOVERIES → NEW BUSINESS PLANS

Investment Committee

Review

APPROVED BUSINESS PLANS

Mission Bay Capital

NEW COMPANY

$$$

$$$

qb3
QB3 helping to bridge the “valley of death”

Innovation Toolkit: A coordinated suite of services to accelerate the commercialization of UC discoveries
QB3 dedicated to innovation

Douglas Crawford, Ph.D.
Associate Director, QB3
Managing Director, Mission Bay Capital
douglas.crawford@ucsf.edu